234 related articles for article (PubMed ID: 35194731)
21. The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Le D; Speers C; Thompson L; Gondara L; Nichol A; Lohrisch C
Cancer; 2020 Mar; 126(5):971-977. PubMed ID: 31750938
[TBL] [Abstract][Full Text] [Related]
22. Real-world outcomes in metastatic HR+/HER2-, HER2+ and triple negative breast cancer after start of first-line therapy.
W DeClue R; Fisher MD; Gooden K; Walker MS; Le TK
Future Oncol; 2023 Apr; 19(13):909-923. PubMed ID: 37191097
[TBL] [Abstract][Full Text] [Related]
23. Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY.
Balmaña J; Fasching PA; Couch FJ; Delaloge S; Labidi-Galy I; O'Shaughnessy J; Park YH; Eisen AF; You B; Bourgeois H; Gonçalves A; Kemp Z; Swampillai A; Jankowski T; Sohn JH; Poddubskaya E; Mukhametshina G; Aksoy S; Timcheva CV; Park-Simon TW; Antón-Torres A; John E; Baria K; Gibson I; Gelmon KA;
Breast Cancer Res Treat; 2024 Apr; 204(2):237-248. PubMed ID: 38112922
[TBL] [Abstract][Full Text] [Related]
24. First-line treatment patterns and clinical outcomes in patients with HER2-positive and hormone receptor-positive metastatic breast cancer from registHER.
Tripathy D; Kaufman PA; Brufsky AM; Mayer M; Yood MU; Yoo B; Quah C; Yardley D; Rugo HS
Oncologist; 2013; 18(5):501-10. PubMed ID: 23652380
[TBL] [Abstract][Full Text] [Related]
25. De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry.
Tripathy D; Brufsky A; Cobleigh M; Jahanzeb M; Kaufman PA; Mason G; O'Shaughnessy J; Rugo HS; Swain SM; Yardley DA; Chu L; Li H; Antao V; Hurvitz SA
Oncologist; 2020 Feb; 25(2):e214-e222. PubMed ID: 32043771
[TBL] [Abstract][Full Text] [Related]
26. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
27. First-line real-world treatment patterns and survival outcomes in women younger or older than 40 years with metastatic breast cancer in the real-life multicenter French ESME cohort.
Galvin A; Courtinard C; Bouteiller F; Gourgou S; Dalenc F; Jacot W; Arnedos M; Bailleux C; Dieras V; Petit T; Emile G; Dubray-Longeras P; Frenel JS; Bachelot T; Mailliez A; Brain E; Desmoulins I; Massard V; Patsouris A; Goncalves A; Grinda T; Delaloge S; Bellera C
Eur J Cancer; 2024 Jan; 196():113422. PubMed ID: 37977105
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes and metastatic behavior between de novo versus recurrent HER2-positive metastatic breast cancer: A 17-year single-institution cohort study at Taipei Veterans General Hospital.
Cheng HF; Tsai YF; Huang CC; Lien PJ; Wang YL; Hsu CY; Chen YJ; Liu CY; Chao TC; Lin YS; Feng CJ; Chiu JH; Chau GY; Tseng LM
J Chin Med Assoc; 2022 Jan; 85(1):88-94. PubMed ID: 34561409
[TBL] [Abstract][Full Text] [Related]
29. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD
J Surg Res; 2024 Jul; 299():217-223. PubMed ID: 38776577
[TBL] [Abstract][Full Text] [Related]
30. Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort.
Darlix A; Louvel G; Fraisse J; Jacot W; Brain E; Debled M; Mouret-Reynier MA; Goncalves A; Dalenc F; Delaloge S; Campone M; Augereau P; Ferrero JM; Levy C; Fumet JD; Lecouillard I; Cottu P; Petit T; Uwer L; Jouannaud C; Leheurteur M; Dieras V; Robain M; Chevrot M; Pasquier D; Bachelot T
Br J Cancer; 2019 Dec; 121(12):991-1000. PubMed ID: 31719684
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update.
Moy B; Rumble RB; Come SE; Davidson NE; Di Leo A; Gralow JR; Hortobagyi GN; Yee D; Smith IE; Chavez-MacGregor M; Nanda R; McArthur HL; Spring L; Reeder-Hayes KE; Ruddy KJ; Unger PS; Vinayak S; Irvin WJ; Armaghani A; Danso MA; Dickson N; Turner SS; Perkins CL; Carey LA
J Clin Oncol; 2021 Dec; 39(35):3938-3958. PubMed ID: 34324366
[TBL] [Abstract][Full Text] [Related]
32. Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
DeBusk K; Ike C; Lindegger N; Schwartz N; Surinach A; Liu Y; Forero-Torres A
J Manag Care Spec Pharm; 2022 Jun; 28(6):657-666. PubMed ID: 35621719
[No Abstract] [Full Text] [Related]
33. Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study.
Xu B; Sun T; Shi Y; Cui J; Yin Y; Ouyang Q; Liu Q; Zhang Q; Chen Y; Wang S; Wang X; Tong Z; Zhong Y; Wang J; Yan M; Yan X; Wang C; Feng J; Wang X; Hu G; Cheng Y; Ge R; Zhu Z; Zhang W; Shao Z
Breast Cancer Res Treat; 2023 Feb; 197(3):489-501. PubMed ID: 36459284
[TBL] [Abstract][Full Text] [Related]
34. The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis.
Kuksis M; Gao Y; Tran W; Hoey C; Kiss A; Komorowski AS; Dhaliwal AJ; Sahgal A; Das S; Chan KK; Jerzak KJ
Neuro Oncol; 2021 Jun; 23(6):894-904. PubMed ID: 33367836
[TBL] [Abstract][Full Text] [Related]
35. BRCA testing and outcomes in women with breast cancer.
Stenehjem DD; Telford C; Unni SK; Bauer H; Sainski A; Deka R; Schauerhamer MB; Ye X; Tak CR; Ma J; Dalvi TB; Gutierrez L; Kaye JA; Tyczynski JE; Brixner DI; Biskupiak JE
Breast Cancer Res Treat; 2021 Apr; 186(3):839-850. PubMed ID: 33389410
[TBL] [Abstract][Full Text] [Related]
36. Incidence, risk factors and survival of patients with brain metastases at initial metastatic breast cancer diagnosis in China.
Li Y; Li Q; Mo H; Guan X; Lin S; Wang Z; Chen Y; Zhang Y; Zhang D; Chen S; Cai R; Wang J; Luo Y; Fan Y; Yuan P; Zhang P; Li Q; Ma F; Xu B
Breast; 2021 Feb; 55():30-36. PubMed ID: 33310633
[TBL] [Abstract][Full Text] [Related]
37. Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
Finn RS; Press MF; Dering J; Arbushites M; Koehler M; Oliva C; Williams LS; Di Leo A
J Clin Oncol; 2009 Aug; 27(24):3908-15. PubMed ID: 19620495
[TBL] [Abstract][Full Text] [Related]
38. Endocrine therapy or chemotherapy as first-line therapy in hormone receptor-positive HER2-negative metastatic breast cancer patients.
Jacquet E; Lardy-Cléaud A; Pistilli B; Franck S; Cottu P; Delaloge S; Debled M; Vanlemmens L; Leheurteur M; Guizard AV; Laborde L; Uwer L; Jacot W; Berchery D; Desmoulins I; Ferrero JM; Perrocheau G; Courtinard C; Brain E; Chabaud S; Robain M; Bachelot T
Eur J Cancer; 2018 May; 95():93-101. PubMed ID: 29655061
[TBL] [Abstract][Full Text] [Related]
39. Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis.
Gargiulo P; Pensabene M; Milano M; Arpino G; Giuliano M; Forestieri V; Condello C; Lauria R; De Placido S
BMC Cancer; 2016 Jul; 16():375. PubMed ID: 27377827
[TBL] [Abstract][Full Text] [Related]
40. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry.
Gampenrieder SP; Rinnerthaler G; Tinchon C; Petzer A; Balic M; Heibl S; Schmitt C; Zabernigg AF; Egle D; Sandholzer M; Singer CF; Roitner F; Hager C; Andel J; Hubalek M; Knauer M; Greil R
Breast Cancer Res; 2021 Dec; 23(1):112. PubMed ID: 34906198
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]